Daysee 91 Day Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Daysee 91 Day Availability in 2026

Extended-cycle oral contraceptives like Daysee 91 Day (Levonorgestrel 0.15 mg / Ethinyl Estradiol 0.03 mg, 84 tablets + Ethinyl Estradiol 0.01 mg, 7 tablets) occupy a unique niche in contraceptive care. They offer patients the convenience of only four withdrawal bleeds per year while using a well-established hormonal combination. But that niche positioning also creates challenges for your patients when it comes to finding the medication at their local pharmacy.

This briefing covers the current availability picture, prescribing considerations, therapeutic alternatives, and tools you can recommend to help your patients access their medication.

Current Status: Is Daysee 91 Day in Shortage?

As of Q1 2026, Daysee 91 Day is not listed on the FDA Drug Shortage Database. Lupin Pharmaceuticals, the manufacturer, has not issued any supply discontinuation notices.

However, clinicians should be aware that patients frequently report difficulty filling prescriptions for Daysee and other extended-cycle contraceptives at retail pharmacies. This is generally attributable to:

• Low per-pharmacy dispensing volume: Extended-cycle formulations account for a small share of total oral contraceptive prescriptions, leading many pharmacies to stock them in limited quantities or on a special-order basis.
• Generic market fragmentation: The same Levonorgestrel/Ethinyl Estradiol extended-cycle formulation is available under multiple brand and generic names (Seasonique, Camrese, Ashlyna, Amethia, Simpesse, Jaimiess, Rivelsa, Fayosim, Dolishale). Pharmacies may stock one version but not others, creating a mismatch with what's prescribed.
• Formulary-driven substitution: Insurance plans often designate a preferred generic, which may differ from the product written on the prescription. This can cause fill delays if the pharmacy needs prescriber authorization for substitution.

Timeline: Extended-Cycle Contraceptive Supply Landscape

For historical context:

• 2003: Seasonale (Levonorgestrel/EE, 84+7 placebo) becomes the first FDA-approved extended-cycle OC.
• 2006: Seasonique launches with the 84+7 low-dose EE formulation — the same design used by Daysee.
• 2012–2018: Multiple generics enter the market (Camrese, Amethia, Ashlyna, Daysee, etc.), increasing competition and lowering prices.
• 2020–2024: Intermittent supply disruptions across various oral contraceptive manufacturers, driven by pandemic-related supply chain issues, raw material constraints, and increased demand.
• 2025–2026: Supply has broadly stabilized. No formal shortages reported. However, pharmacy-level stock-outs persist for lower-volume products like extended-cycle OCs.

Prescribing Implications

When prescribing Daysee 91 Day or any extended-cycle Levonorgestrel/EE product, consider these practical steps to improve your patient's fill rate:

1. Allow Generic Substitution

Unless there is a specific clinical reason to require the Daysee brand, avoid writing "Dispense As Written" (DAW). Allowing generic substitution gives the pharmacy flexibility to fill with whatever AB-rated equivalent is in stock — Camrese, Ashlyna, Simpesse, Rivelsa, or another available generic.

2. Prescribe by Generic Name When Possible

Writing the prescription as "Levonorgestrel 0.15 mg / Ethinyl Estradiol 0.03 mg, 84 tablets + Ethinyl Estradiol 0.01 mg, 7 tablets (91-day extended cycle)" maximizes pharmacy flexibility. This is especially helpful for patients who use multiple pharmacies or mail-order services.

3. Discuss Formulary Options Proactively

Check with the patient's insurance plan to determine which extended-cycle OC is on their formulary. Prescribing the preferred formulary product reduces the likelihood of fill delays, prior authorization requirements, or unexpected out-of-pocket costs.

4. Consider Mail-Order Pharmacy

For patients on stable extended-cycle regimens, mail-order pharmacy is an excellent option. The 91-day supply aligns well with the typical 90-day mail-order dispensing model, and mail-order pharmacies tend to have more consistent inventory for specialized products.

Availability Picture: Where Patients Can Find Daysee

To help patients locate Daysee 91 Day or its equivalents, recommend the following resources:

• Medfinder for Providers: medfinder.com/providers — a tool designed specifically for clinical teams to check real-time pharmacy availability and help patients find their medications in stock.
• Independent pharmacies: Often have more flexible ordering and may carry niche products that chains do not.
• Specialty and compounding pharmacies: While Daysee doesn't require compounding, specialty pharmacies sometimes carry a broader range of brand and generic contraceptives.

Cost and Access Considerations

Under the Affordable Care Act, most commercial insurance plans must cover at least one product in each FDA-approved contraceptive category at no cost sharing. For extended-cycle OCs, this typically means coverage of at least one generic version at $0 copay.

Key cost data for uninsured or underinsured patients:

• Brand Daysee cash price: $200–$300 per 91-day pack
• Generic equivalents with coupon: $27–$60 per pack (GoodRx, SingleCare, RxSaver)
• Patient assistance: Lupin Pharmaceuticals Patient Assistance Program (through NeedyMeds/RxAssist) may provide free medication to qualifying patients

Encourage uninsured patients to explore discount programs and patient assistance options. For details, direct them to: How to Save Money on Daysee 91 Day.

Therapeutic Alternatives

If a patient cannot access any Levonorgestrel/EE extended-cycle product, consider these alternatives:

• Continuous use of a standard 28-day OC: Prescribing a monophasic combined OC (e.g., Levonorgestrel/EE 0.15/0.03) with instructions to skip the placebo week and start a new pack immediately is an evidence-based approach to achieve continuous or extended-cycle contraception using widely available products.
• LoSeasonique / Camrese Lo: A lower-dose extended-cycle option (Levonorgestrel 0.1 mg / EE 0.02 mg, 84 tablets + EE 0.01 mg, 7 tablets) for patients who experience estrogen-related side effects.
• Quartette: An extended-cycle OC with an escalating-dose design (Levonorgestrel doses increase across the 84-day active phase). May be preferred for patients with persistent breakthrough bleeding on fixed-dose regimens.
• Non-oral options: For patients who struggle with daily pill adherence over a 91-day cycle, consider the contraceptive patch (Xulane), vaginal ring (NuvaRing, Annovera), or long-acting reversible contraceptives (IUDs, implants).

Tools and Resources for Your Practice

• Medfinder for Providers — Real-time medication availability search
• Provider's Guide: Helping Patients Find Daysee 91 Day
• Provider's Guide: Helping Patients Save Money on Daysee 91 Day
• FDA Drug Shortage Database: accessdata.fda.gov
• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages

Looking Ahead

The extended-cycle OC market is mature, with multiple generic manufacturers supplying the U.S. market. Barring unexpected manufacturing disruptions, supply is expected to remain stable through 2026. The primary access challenge for patients continues to be pharmacy-level stocking decisions rather than true product shortages.

Proactive prescribing — allowing generic substitution, checking formularies, and directing patients to availability tools — remains the most effective way to ensure your patients maintain uninterrupted access to their extended-cycle contraception.

Final Thoughts

Daysee 91 Day and its generic equivalents are not in formal shortage, but pharmacy-level availability gaps continue to affect patients. By prescribing flexibly, educating patients about their generic options, and leveraging tools like Medfinder for Providers, you can help minimize disruptions to your patients' contraceptive care.